FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to drugs used for treating chronic kidney disease in diabetes mellitus. Dulaglutide 1.5 mg once a week and dapagliflozin 10 mg in the morning are administered. Additionally, dalargin – 0.1% solution is injected intramuscularly in dose of 1.0 ml 2 times a day, for 20 days, in courses every 3 months, in total 4 courses.
EFFECT: invention provides an effective method of treating chronic kidney disease in diabetes mellitus.
1 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING DIABETES MELLITUS IN COMPLEX WITH DALARGIN | 2023 |
|
RU2816021C1 |
| METHOD OF TREATING CLIMACTERIC SYNDROME IN WOMEN | 2024 |
|
RU2821826C1 |
| METHOD OF TREATING HYPOTHYROIDISM WITH DALARGIN | 2023 |
|
RU2814749C1 |
| METHOD OF TREATING ENDOCRINE AUTOIMMUNE OPHTHALMOPATHY | 2024 |
|
RU2819981C1 |
| METHOD OF TREATING KNEE OSTEOARTHRITIS | 2024 |
|
RU2822321C1 |
| METHOD OF TREATING PSORIASIS | 2024 |
|
RU2819488C1 |
| METHOD OF ASSESSING EFFECTIVENESS OF VITAMIN D THERAPY FOR CHRONIC KIDNEY DISEASE IN PERSON WITH DIABETES MELLITUS | 2022 |
|
RU2806735C1 |
| METHOD FOR DIAGNOSTICS OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2017 |
|
RU2641964C1 |
| METHOD OF TREATING BENIGN PARATHYROID GROWTHS | 2023 |
|
RU2813943C1 |
| METHOD OF PERSONALIZED TREATMENT OF CHRONIC RENAL DISEASE IN PATIENTS WITH DIABETIC NEPHROPATHY | 2018 |
|
RU2687256C1 |
